The global aspirin drug market share is expected to account for USD 2,938.2 million in 2024 and expand at a consistent CAGR of 3.8% to reach a valuation of USD 4,236.9 million by 2034. According to a recent study by Future Market Insights, a combination aspirin drug is leading the market with a share of about 68% in 2023 within the global market.
Growth in the aspirin industry could be attributed to an increase in conditions like arthritis, pain, and inflammation. The rising incidence of chronic conditions like renal disorders, cardiovascular diseases, and brain strokes among people is driving the aspirin drug market forward. The initiative taken by public and private organizations to spread awareness about myocardial infarction is expected to elevate the market scope further.
| Data Points | Market Insights |
|---|---|
| Aspirin Drug Market Size, 2023 | USD 2,831.8 million |
| Aspirin Drug Market Size, 2024 | USD 2,938.2 million |
| Aspirin Drug Market Size, 2034 | USD 4,236.9 million |
| CAGR 2024 to 2034 | 3.8% |
Explore FMI!
Book a free demo
| Attributes | Details |
|---|---|
| Aspirin Drug Market Size (2019) | USD 2,471.6 million |
| Aspirin Drug Market Size (2023) | USD 2,831.8 million |
| Aspirin Drug Market CAGR % (2019 to 2023) | 3.4% |
The market value for aspirin drugs was around 18.6% of the overall USD 15.1 billion of the global non-steroidal anti-inflammatory drugs (NSAIDs) market in 2023.
The sale of aspirin drugs expanded at a CAGR of 3.4% from 2019 to 2023 owing to rising diseases like pain, fever, inflammation, rheumatoid arthritis, and systemic lupus erythematosus. This can be attributed to the consumption of aspirin as a blood-thinning agent in treating chronic diseases. Further, it reduces the risk of blood clot formation and treats minor pain and aches.
The aspirin drug market continues to expand due to new drug research, commercial use, and development breakthroughs. For instance, in July 2019, Dr Reddy's Laboratories launched rosuvastatin, aspirin, and clopidogrel FDC under Rozat Gold.
Over the forecast period, the market is projected to be driven by the pharmaceutical industry's rising efforts in discovering novel treatments to treat chronic diseases. The global aspirin drug market is expected to register a CAGR of 3.8% from 2024 to 2034.
| Historical CAGR % (2019 to 2023) | 3.4% |
|---|---|
| Forecast CAGR % (2024 to 2034) | 3.8% |
| Country | The United States |
|---|---|
| CAGR (2024 to 2034) | 3.9% |
The United States is expected to seize a 25.7% global market share in 2024. Recent market projections indicate continued profitable prospects in North America. The primary driver of the target market is the increasing need for aspirin to manage chronic pain. Chronic pain, especially in adults, is rising in the United States due to sitting for an extended time. Aspirin drug acts as a painkiller for chronic pain. For instance, in a report published by the Centers for Disease Control and Prevention, a prevalence of chronic pain as well as high-impact chronic pain was found among United States adults, with 4% (50.0 million) suffering from chronic pain and 8.0% (19.6 million) from high-impact chronic pain, respectively. These are key driving factors propelling this region's demand for aspirin drugs.
| Country | Germany |
|---|---|
| CAGR (2024 to 2034) | 3.1% |
In Europe, Germany is anticipated to acquire a significant share of 26.5% of the aspirin drug market in 2024. In 2024, the German aspirin drug market is predicted to reach USD 187.8 million, followed by a CAGR of 3.1% through 2034.
| Country | The United Kingdom |
|---|---|
| CAGR (2024 to 2034) | 3.2% |
The aspirin drug market in the United Kingdom is expected to acquire a mere 3.2% global market share in 2024. In Europe, the market share is estimated to be a notable 21.1%. After attaining a market value of USD 88.2 million in 2024, the market is expected to record a CAGR of 3.2% through 2034. The following factors support the regional growth:
| Country | India |
|---|---|
| CAGR (2024 to 2034) | 3.4% |
The aspirin drug market in India is set to exhibit a CAGR of 3.4% in 2034. In India, substantial financing and the launch of several healthcare programs, like Pradhan Mantri Jan Arogya Yojana and Ayushman Bharat, which offer accessible healthcare facilities and reimbursement options to patients receiving healthcare treatment, are boosting the product demand. Other factors leading to product sales are:
| Country | China |
|---|---|
| CAGR (2024 to 2034) | 3.6% |
China holds around 5.4% share in the global market in 2023, owing to the prevalence of increasing cardiovascular diseases like stroke or heart attack. China is one of the leading producers of aspirin drugs. Around two-thirds of aspirin is now produced in China. Drug development of aspirin drugs is significantly increasing in China due to rising research funding. These factors are predicted to drive sales of aspirin drugs in China. Additionally, due to the increase in the production and export of APIs, which accounts for 20% of global output, China is considered one of the top leaders in the region.
| Leading Product Type | Combination |
|---|---|
| CAGR | 4% |
The combination is anticipated to account for 68% value share in 2024. The segment is expected to display a CAGR of 4.0% through 2034. Antiplatelet agents are a class of drugs that include extended-release dipyridamole and a combination of aspirin. A combination of aspirin prevents excessive blood clotting, leading to widespread adoption.
| Leading Dosage Form | Tablets |
|---|---|
| Market Share % (2024) | 3.4% |
The tablets segment is anticipated to hold a market share of 44.8% in 2024. Over the forecast period, the segment is expected to grow gradually, with an estimated CAGR of 3.4% through 2034. Tablets are the easiest and safest way to consume the drug. Further, it helps to alleviate fever and relieve pain from conditions such as toothaches, muscle aches, and the common cold. These factors are increasing the sales of aspirin drugs in tablet form.
| Leading Route of Administration | Oral |
|---|---|
| CAGR | 3.5% |
The oral route of administration usage is more as compared to rectal and parenteral. Topical holds a prominent market share value of 49.8% in 2024, followed by a CAGR of 3.5% through 2034. Owing to its advantages, such as patient compliance, non-invasiveness, and convenience of drug administration, the oral route of administration is the favored method.
| Leading Age Group | Pediatric |
|---|---|
| CAGR | 56.2% |
Pediatrics is projected to hold a market share of 56.2% in 2024. The segment is expected to grow gradually over the forecast period, with an estimated CAGR of 3.8% through 2034. Aspirin drug dosage is quite effective in pediatric populations suffering from diseases like chicken pox and flu-like symptoms. The weak immune system of the pediatric population makes them an easy target for these diseases. Hence, aspirin drug is commonly used in the medicine of the pediatric population.
| Leading Distribution Channel | Retail Pharmacies |
|---|---|
| CAGR | 3.4% |
Retail Pharmacies are anticipated to register a prominent share of 44.0% in the aspirin drug market in 2024, with a CAGR of 3.4% through 2034. The easy availability of drugs in all forms in retail pharmacies supports the increasing purchases of medicines from these pharmacies.
The market for the production of aspirin drugs is fragmented, with several competitors. These businesses are employing strategies including collaborations, partnerships, mergers and acquisitions, and new drug releases to meet consumer demand and amplify their client base. Governments across the globe are also taking initiatives to invest in life-saving drugs like aspirin.
Similarly, the team at Future Market Insights has tracked recent developments related to pharmaceutical companies manufacturing aspirin drugs, which are available in the full report.
The aspirin drug market is expected to be worth USD 2,938.2 million in 2024.
The market is predicted to expand at a CAGR of 3.8% through 2034.
The market is anticipated to account for USD 4,236.9 million by 2034.
China is predicted to provide high growth opportunities.
Health professionals significantly prescribe combination aspirin drug.
Aspirin Drug Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
